News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Wendi Qu

Articles by Wendi Qu

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

ByErica L. Mayer, MD, MPH,Mary Lou Smith,Annie Guérin,Dominick Latrémouille-Viau,Nisha C. Hazra,Yan Meng,Wendi Qu,Remi Bellefleur,Vaidyanathan Ganapathy,Liz Santarsiero,Robert Morlock,Maryam Lustberg

August 2nd 2024

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

© 2025 MJH Life Sciences^®

All rights reserved.